X
BMS and Roche look to Halozyme drug delivery for IO advantage
https://pharmaphorum.com/news/bms-roche-look-halozyme-drug-delivery-io-advantage/
immuno-oncology
Soriot commits to AstraZeneca as shares slide
July 27, 2017
Immuno-oncology drugs: key to the Cancer Moonshot?
June 21, 2017Assessing the global challenges inhibiting immuno-oncology market access.
Keytruda wins another first with approval based on biomarkers
May 24, 2017For the first time, FDA approves drug on the basis of biomarkers, rather than location.
The cancer challenge: the quest for a cure is only half the battle
May 18, 2017The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Deep Dive: Oncology magazine launched today
May 9, 2017Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
With all eyes on IO, Tagrisso could be AZ’s ace card
February 2, 2017
